Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.

Prazosin cuts rate of drinking in patients with alcohol use disorder

10 Sep 2018
How to identify doctors hooked on drugs and alcohol

The α-1 adrenergic receptor antagonist prazosin appears to be an effective treatment for alcohol use disorder, according to a recent study.

“Prazosin holds promise as a harm-reduction pharmacologic treatment for alcohol use disorder and deserves further evaluation by independent research groups,” the authors said.

A total of 92 participants with alcohol use disorder but without post-traumatic stress disorder were randomized to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing of 4 mg in morning and in the afternoon and 8 mg at bedtime by the end of week 2.

Medical management was the behavioural platform. Data on alcohol consumption were provided by participants daily. The authors assessed the impact of prazosin vs placebo on number of drinks per week, number of drinking days per week and number of heavy drinking days per week using generalized linear mixed-effects models.

Of the participants, 80 completed the titration and were included in the primary analyses. A significant association was seen between condition and week for both number of drinks and number of heavy drinking days. Participants in the prazosin condition had a greater reduction in the rate of drinking and the probability of heavy drinking compared with those in the placebo condition over time.

In addition, there was a higher incidence of drowsiness and oedema among participants in the prazosin vs the placebo condition.

“Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.